#USA #Toronto #CFO Transition #IM Cannabis #Uri Birenberg

IM Cannabis Corp. Announces CFO Departure

In a recent development, IM Cannabis Corp. (NASDAQ: IMCC), an established player in the international medical cannabis sector, has disclosed that its Chief Financial Officer, Uri Birenberg, is set to step down for personal reasons. The announcement, made on October 29, 2025, highlights both the internal decision-making of IM Cannabis and the transition plans for its leadership.

Birenberg, who has served as CFO for the past two years, will continue in his role until January 5, 2026. During this period, he will assist the company in a structured transition to ensure a smooth handover of responsibilities to a successor. The CEO of IM Cannabis, Oren Shuster, expressed gratitude towards Birenberg for his contributions during his tenure, remarking on the value he brought to the company’s leadership team.

"On behalf of our entire team, I want to thank Uri for his commitment and contributions to IMC. Over the past two years, he has been a valued member of our leadership, and we wish him every success in his next chapter," stated Shuster.

In response to his impending departure, Uri Birenberg commented, "It has been a great pleasure to serve as the Company's Chief Financial Officer over the past two years. I have the highest confidence in the Company and am grateful for the opportunity to work with one of the most dedicated teams in the cannabis industry."

IM Cannabis Corp. operates in two of the world’s most significant medical cannabis markets, Israel and Germany. The company prides itself on providing premium cannabis products and leveraging a data-driven approach along with a globally sourced product supply chain. With a commitment to compliance and responsible growth, IM Cannabis aims to amplify its brand and become a key player in the global cannabis market.

The firm’s extensive operational ecosystem includes the importation and distribution of medical cannabis products to patients in Israel, supported by years of proprietary data and patient insights. It also runs medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs aimed at ensuring quality control throughout the entire value chain.

In Germany, IM Cannabis functions through Adjupharm GmbH, distributing cannabis to pharmacies for medical patients, reinforcing its international operational capabilities.

As the company embarks on the search for a new CFO, stakeholders remain hopeful that the transition will not interrupt the ongoing commitment to delivering quality cannabis solutions to patients in need.

As part of its forward-looking strategy, IM Cannabis emphasizes that this transition is expected without disruption to its operational integrity. However, the management acknowledges the inherent risks and uncertainties involved in leadership transitions, particularly in a highly regulated industry like cannabis.

Disclaimer: The content of this announcement contains forward-looking statements as defined within applicable securities laws, indicating the company’s ability to navigate through future transitions and regulatory landscapes while maintaining compliance. Stakeholders are encouraged to stay informed on further developments as the search for Birenberg’s successor progresses.

For further information about IM Cannabis Corp., or updates regarding the leadership transition, please contact:

Anna Taranko
Director, Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster
CEO, IM Cannabis Corp.
[email protected]

IM Cannabis remains committed to its mission and is optimistic about the opportunity to enhance its operations as it looks forward to a robust future in the cannabis industry.